Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval)
specificA rare, aggressive type of chordoma characterized by loss of SMARCB1 expression. It affects children and occasionally young adults. Females are affected twice as frequently as males. It usually arises in the axial skeleton. It is composed of sheets or nests of malignant epithelioid cells with abundant eosinophilic cytoplasm. The prognosis is poor.
8
Centers
0
Active Trials
—
Cancer Funding
Top Centers for Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval)(8)
Ranked by research excellence score (trials · grants · publications). Methodology →
| # | Center | Score |
|---|---|---|
| 1 | Memorial Sloan Kettering Cancer CenterNew York, NY NCI Comprehensive | 56.2 |
| 2 | Dana-Farber Cancer InstituteBoston, MA NCI Comprehensive | 56.2 |
| 3 | Fred Hutch Cancer CenterSeattle, WA NCI Comprehensive | 56.2 |
| 4 | University of Colorado Cancer CenterAurora, CO NCI Comprehensive | 56.2 |
| 5 | University of Illinois Cancer CenterChicago, IL | 56.2 |
| 6 | Boston University Cancer CenterBoston, MA | 56.2 |
| 7 | University of Cincinnati Cancer CenterCincinnati, OH | 56.2 |
| 8 | Princess Margaret Cancer CentreToronto, ON | 56.2 |
Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →